This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

StemCells, Inc. Adds Eliseo Salinas To Advise On Product Development Strategy For Its Proprietary Human Neural Stem Cells

NEWARK, Calif., Oct. 18, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced it has retained Eliseo Oreste Salinas, MD, MSc, on an exclusive basis, to help formulate and execute the clinical translation and product development strategy for the Company's proprietary HuCNS-SC® cells (purified human neural stem cells). Dr. Salinas was most recently Executive Vice President, Head of Development and Chief Medical Officer at Elan Pharmaceuticals. He has extensive experience and expertise developing therapeutic products for central nervous system (CNS) disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan.  

"With two early stage clinical trials in the brain successfully completed and two other trials underway in the spinal cord and the eye, we have reached an important inflection point in our pioneering efforts to bring neural stem cell-based  therapeutics into clinical practice," said Martin McGlynn, President and CEO of StemCells, Inc. "Eliseo will help us prioritize and right size our product development strategy and help us build a world class development team to bring this exciting technology to market.  His broad CNS experience includes Alzheimer's disease, multiple sclerosis, Parkinson's disease, attention deficit disorder, epilepsy, and stroke.  To date, he has been responsible for eight successful NDAs or BLAs and four successful European submissions. This global regulatory experience should prove invaluable as we build on our great science and early clinical data to accelerate the transition into product development."  

StemCells has a broad and expanding clinical development program for its HuCNS-SC cells. The Company has ongoing Phase I/II clinical trials in chronic thoracic spinal cord injury and dry age-related macular degeneration, and is planning for a controlled Phase II study in Pelizaeus-Merzbacher Disease.   In addition, as contemplated by the recently announced awards by the California Institute for Regenerative Medicine, the Company anticipates pursuing INDs for both cervical spinal cord injury and Alzheimer's disease over the next four years. 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.03 -67.42 -0.39%
S&P 500 1,997.46 -5.91 -0.30%
NASDAQ 4,583.1820 +2.9110 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs